Research programme: ADAM inhibitors - Incyte

Drug Profile

Research programme: ADAM inhibitors - Incyte

Alternative Names: A disintegrin and metalloproteinase inhibitors - Incyte; HER-2 sheddase inhibitors - Incyte; INCB 3619

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Incyte Corporation
  • Class Hydroxamic acids; Piperidines; Sulfonamides
  • Mechanism of Action Epidermal growth factor inhibitors; Metalloprotease inhibitors; Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
  • 03 Sep 2007 Data presented at the 234th American Chemical Society National Meeting (234th-ACS-2007) pharmacodynamics section
  • 19 Jan 2006 Data presented at the 28th Annual San Antonio Breast Cancer Symposium (SABCS-2005) have been added to the adverse events and Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top